Itopride

# Itopride ## Overview - **Classification**: Prokinetic agent, Gastric motility enhancer - **Mechanism**: Dual action: Dopamine D2 receptor antagonist (increases acetylcholine release) and acetylcholinesterase inhibitor (prevents acetylcholine degradation). Promotes gastric emptying. ## Primary Indications 1. **Functional Dyspepsia (FD)** - Management of gastrointestinal symptoms like bloating, early satiety, epigastric pain/discomfort, nausea, vomiting. 2. **Non-ulcer Dyspepsia (NUD)** - Relief of dyspeptic symptoms not attributed to structural abnormalities. ## Adult Dosing ### Standard Dosing **Functional Dyspepsia/NUD** - **Dose**: **50 mg** - **Frequency**: Three times daily (TID) - **Route**: Oral - **Duration**: Typically 2-8 weeks, re-evaluate response. - **Maximum Dose**: **150 mg/day** ### Dose Adjustments - **Renal Impairment**: Use with **caution**. Data limited. Consider dose reduction or extended interval in severe impairment. - **Hepatic Impairment**: Use with **caution**. Data limited. - **Elderly Patients**: Start with **caution**, consider lower initial dose (e.g., **25 mg TID**) due to potential increased sensitivity and co-morbidities. ## Pediatric Dosing ### Neonates (0-28 days) - **Special Notes**: **Not recommended**. Insufficient data on efficacy and safety in this age group. ### Infants (1-12 months) - **Special Notes**: **Not recommended**. Insufficient data on efficacy and safety in this age group. ### Children (1-12 years) - **Special Notes**: **Not generally recommended** due to limited safety and efficacy data. - **Limited Data**: Some studies (off-label use in specific regions) have used **1 mg/kg/day** divided TID for children >6 years. - **Maximum**: **150 mg/day** (or adult dose equivalent). **Only under specialist supervision.** ### Adolescents (13-18 years) - **Special Notes**: **Not generally recommended**. If used under specialist guidance, adult dosing of **50 mg TID** may be considered. - **Maximum**: **150 mg/day**. ## Safety Information ### Contraindications - **Absolute**: Gastrointestinal hemorrhage, mechanical obstruction, or perforation. - **Absolute**: Hypersensitivity to itopride or any excipients. - **Relative**: Prolactinoma (itopride can increase prolactin levels). - **Relative**: Parkinson's disease (dopamine antagonism may worsen symptoms). ### Common Adverse Effects - **Common (1-10%)**: Headache, dizziness, abdominal pain, diarrhea. - **Common (1-10%)**: Increased prolactin levels (may lead to galactorrhea, gynecomastia, menstrual irregularities). - **Less Common (0.1-1%)**: Nausea, constipation, rash, tremor. ### Key Drug Interactions - **Anticholinergic Drugs (e.g., Atropine)**: May reduce the prokinetic effect of itopride. Avoid concomitant use. - **CYP2C19 Inhibitors/Substrates**: Itopride is primarily metabolized by flavin-containing monooxygenase (FMO), but it may inhibit CYP2C19. Clinical significance generally low. - **Drugs with narrow therapeutic index**: Monitor closely if co-administered, though Itopride's interaction profile is relatively benign. ## Monitoring & Follow-up - **Before Treatment**: Assess baseline GI symptoms. - **During Treatment**: Monitor for symptom improvement and adverse effects (GI, CNS, endocrine). - **Clinical Signs**: Worsening GI symptoms, new-onset headache/dizziness, menstrual changes, breast tenderness/discharge. ## Clinical Pearls - 💡 **Tip 1**: Administer **before meals** for optimal effectiveness. - 💡 **Tip 2**: Primarily indicated for functional dyspepsia, not a first-line agent for gastroesophageal reflux disease (GERD). - 💡 **Tip 3**: May elevate prolactin levels; educate patients on potential endocrine side effects, especially with long-term use. - 💡 **Tip 4**: Pediatric use is generally **not recommended** due to limited safety and efficacy data; use only under specialist guidance. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.